世界の二次性副甲状腺機能亢進症治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Secondary Hyperparathyroidism Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z5154
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、99ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、二次性副甲状腺機能亢進症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（手術、治療薬、ビタミンD、カルシウム受容体刺激薬、リン吸着剤）、用途別市場規模（病院薬局、小売薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・二次性副甲状腺機能亢進症治療の市場動向
・企業の競争状況、市場シェア
・二次性副甲状腺機能亢進症治療の種類別市場規模（手術、治療薬、ビタミンD、カルシウム受容体刺激薬、リン吸着剤）
・二次性副甲状腺機能亢進症治療の用途別市場規模（病院薬局、小売薬局）
・二次性副甲状腺機能亢進症治療の北米市場規模2016-2027（アメリカ、カナダ）
・二次性副甲状腺機能亢進症治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・二次性副甲状腺機能亢進症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・二次性副甲状腺機能亢進症治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・二次性副甲状腺機能亢進症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Amgen、OPKO Health、AbbVie、Astellas Pharma、Roche、KAI Pharmaceuticals、Kyowa Hakko Kirin、Leo Pharma、Takeda、Sanofi、Deltanoid Pharmaceuticals）
・結論

Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia and associated hyperplasia of the glands.
In the treatment of secondary hyperparathyroidism due to chronic kidney disease on dialysis calcimimetics do not appear to affect the risk of early death. It does decrease the need for a parathyroidectomy but caused more issues with low blood calcium levels and vomiting.

Market Analysis and Insights: Global Secondary Hyperparathyroidism Treatment Market
The global Secondary Hyperparathyroidism Treatment market size is projected to reach US$ 4471.4 million by 2026, from US$ 3143.6 million in 2019, at a CAGR of 5.1% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Secondary Hyperparathyroidism Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Secondary Hyperparathyroidism Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Secondary Hyperparathyroidism Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Secondary Hyperparathyroidism Treatment market.

Global Secondary Hyperparathyroidism Treatment Scope and Market Size
Secondary Hyperparathyroidism Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Secondary Hyperparathyroidism Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Surgery
Drugs
Vitamin D
Calcimimetics
Phosphate Binders

Segment by Application
Hospital Pharmacies
Retail Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Amgen
OPKO Health
AbbVie
Astellas Pharma
Roche
KAI Pharmaceuticals
Kyowa Hakko Kirin
Leo Pharma
Takeda

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Surgery
1.2.3 Drugs
1.2.4 Vitamin D
1.2.5 Calcimimetics
1.2.6 Phosphate Binders
1.3 Market by Application
1.3.1 Global Secondary Hyperparathyroidism Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Secondary Hyperparathyroidism Treatment Market Perspective (2016-2027)
2.2 Secondary Hyperparathyroidism Treatment Growth Trends by Regions
2.2.1 Secondary Hyperparathyroidism Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Secondary Hyperparathyroidism Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Secondary Hyperparathyroidism Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Secondary Hyperparathyroidism Treatment Industry Dynamic
2.3.1 Secondary Hyperparathyroidism Treatment Market Trends
2.3.2 Secondary Hyperparathyroidism Treatment Market Drivers
2.3.3 Secondary Hyperparathyroidism Treatment Market Challenges
2.3.4 Secondary Hyperparathyroidism Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Secondary Hyperparathyroidism Treatment Players by Revenue
3.1.1 Global Top Secondary Hyperparathyroidism Treatment Players by Revenue (2016-2021)
3.1.2 Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Secondary Hyperparathyroidism Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Secondary Hyperparathyroidism Treatment Revenue
3.4 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio
3.4.1 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Secondary Hyperparathyroidism Treatment Revenue in 2020
3.5 Secondary Hyperparathyroidism Treatment Key Players Head office and Area Served
3.6 Key Players Secondary Hyperparathyroidism Treatment Product Solution and Service
3.7 Date of Enter into Secondary Hyperparathyroidism Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Secondary Hyperparathyroidism Treatment Breakdown Data by Type
4.1 Global Secondary Hyperparathyroidism Treatment Historic Market Size by Type (2016-2021)
4.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Type (2022-2027)

5 Secondary Hyperparathyroidism Treatment Breakdown Data by Application
5.1 Global Secondary Hyperparathyroidism Treatment Historic Market Size by Application (2016-2021)
5.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Secondary Hyperparathyroidism Treatment Market Size (2016-2027)
6.2 North America Secondary Hyperparathyroidism Treatment Market Size by Type
6.2.1 North America Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2021)
6.2.2 North America Secondary Hyperparathyroidism Treatment Market Size by Type (2022-2027)
6.2.3 North America Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2027)
6.3 North America Secondary Hyperparathyroidism Treatment Market Size by Application
6.3.1 North America Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2021)
6.3.2 North America Secondary Hyperparathyroidism Treatment Market Size by Application (2022-2027)
6.3.3 North America Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2027)
6.4 North America Secondary Hyperparathyroidism Treatment Market Size by Country
6.4.1 North America Secondary Hyperparathyroidism Treatment Market Size by Country (2016-2021)
6.4.2 North America Secondary Hyperparathyroidism Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Secondary Hyperparathyroidism Treatment Market Size (2016-2027)
7.2 Europe Secondary Hyperparathyroidism Treatment Market Size by Type
7.2.1 Europe Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2021)
7.2.2 Europe Secondary Hyperparathyroidism Treatment Market Size by Type (2022-2027)
7.2.3 Europe Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2027)
7.3 Europe Secondary Hyperparathyroidism Treatment Market Size by Application
7.3.1 Europe Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2021)
7.3.2 Europe Secondary Hyperparathyroidism Treatment Market Size by Application (2022-2027)
7.3.3 Europe Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2027)
7.4 Europe Secondary Hyperparathyroidism Treatment Market Size by Country
7.4.1 Europe Secondary Hyperparathyroidism Treatment Market Size by Country (2016-2021)
7.4.2 Europe Secondary Hyperparathyroidism Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size (2016-2027)
8.2 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Type
8.2.1 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Application
8.3.1 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Region
8.4.1 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Secondary Hyperparathyroidism Treatment Market Size (2016-2027)
9.2 Latin America Secondary Hyperparathyroidism Treatment Market Size by Type
9.2.1 Latin America Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Secondary Hyperparathyroidism Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2027)
9.3 Latin America Secondary Hyperparathyroidism Treatment Market Size by Application
9.3.1 Latin America Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Secondary Hyperparathyroidism Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2027)
9.4 Latin America Secondary Hyperparathyroidism Treatment Market Size by Country
9.4.1 Latin America Secondary Hyperparathyroidism Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Secondary Hyperparathyroidism Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size (2016-2027)
10.2 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Type
10.2.1 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Application
10.3.1 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Country
10.4.1 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Secondary Hyperparathyroidism Treatment Introduction
11.1.4 Amgen Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021)
11.1.5 Amgen Recent Development
11.2 OPKO Health
11.2.1 OPKO Health Company Details
11.2.2 OPKO Health Business Overview
11.2.3 OPKO Health Secondary Hyperparathyroidism Treatment Introduction
11.2.4 OPKO Health Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021)
11.2.5 OPKO Health Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Secondary Hyperparathyroidism Treatment Introduction
11.3.4 AbbVie Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021)
11.3.5 AbbVie Recent Development
11.4 Astellas Pharma
11.4.1 Astellas Pharma Company Details
11.4.2 Astellas Pharma Business Overview
11.4.3 Astellas Pharma Secondary Hyperparathyroidism Treatment Introduction
11.4.4 Astellas Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021)
11.4.5 Astellas Pharma Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Secondary Hyperparathyroidism Treatment Introduction
11.5.4 Roche Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021)
11.5.5 Roche Recent Development
11.6 KAI Pharmaceuticals
11.6.1 KAI Pharmaceuticals Company Details
11.6.2 KAI Pharmaceuticals Business Overview
11.6.3 KAI Pharmaceuticals Secondary Hyperparathyroidism Treatment Introduction
11.6.4 KAI Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021)
11.6.5 KAI Pharmaceuticals Recent Development
11.7 Kyowa Hakko Kirin
11.7.1 Kyowa Hakko Kirin Company Details
11.7.2 Kyowa Hakko Kirin Business Overview
11.7.3 Kyowa Hakko Kirin Secondary Hyperparathyroidism Treatment Introduction
11.7.4 Kyowa Hakko Kirin Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021)
11.7.5 Kyowa Hakko Kirin Recent Development
11.8 Leo Pharma
11.8.1 Leo Pharma Company Details
11.8.2 Leo Pharma Business Overview
11.8.3 Leo Pharma Secondary Hyperparathyroidism Treatment Introduction
11.8.4 Leo Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021)
11.8.5 Leo Pharma Recent Development
11.9 Takeda
11.9.1 Takeda Company Details
11.9.2 Takeda Business Overview
11.9.3 Takeda Secondary Hyperparathyroidism Treatment Introduction
11.9.4 Takeda Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021)
11.9.5 Takeda Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Details
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Secondary Hyperparathyroidism Treatment Introduction
11.10.4 Sanofi Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021)
11.10.5 Sanofi Recent Development
11.11 Deltanoid Pharmaceuticals
11.11.1 Deltanoid Pharmaceuticals Company Details
11.11.2 Deltanoid Pharmaceuticals Business Overview
11.11.3 Deltanoid Pharmaceuticals Secondary Hyperparathyroidism Treatment Introduction
11.11.4 Deltanoid Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021)
11.11.5 Deltanoid Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Surgery
Table 3. Key Players of Drugs
Table 4. Key Players of Vitamin D
Table 5. Key Players of Calcimimetics
Table 6. Key Players of Phosphate Binders
Table 7. Global Secondary Hyperparathyroidism Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Secondary Hyperparathyroidism Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Secondary Hyperparathyroidism Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Secondary Hyperparathyroidism Treatment Market Share by Regions (2016-2021)
Table 11. Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Secondary Hyperparathyroidism Treatment Market Share by Regions (2022-2027)
Table 13. Secondary Hyperparathyroidism Treatment Market Trends
Table 14. Secondary Hyperparathyroidism Treatment Market Drivers
Table 15. Secondary Hyperparathyroidism Treatment Market Challenges
Table 16. Secondary Hyperparathyroidism Treatment Market Restraints
Table 17. Global Secondary Hyperparathyroidism Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Secondary Hyperparathyroidism Treatment Market Share by Players (2016-2021)
Table 19. Global Top Secondary Hyperparathyroidism Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Secondary Hyperparathyroidism Treatment as of 2020)
Table 20. Ranking of Global Top Secondary Hyperparathyroidism Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Secondary Hyperparathyroidism Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Secondary Hyperparathyroidism Treatment Product Solution and Service
Table 24. Date of Enter into Secondary Hyperparathyroidism Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Secondary Hyperparathyroidism Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Secondary Hyperparathyroidism Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Secondary Hyperparathyroidism Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Secondary Hyperparathyroidism Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Secondary Hyperparathyroidism Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Secondary Hyperparathyroidism Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Secondary Hyperparathyroidism Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Secondary Hyperparathyroidism Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Secondary Hyperparathyroidism Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Secondary Hyperparathyroidism Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Secondary Hyperparathyroidism Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Secondary Hyperparathyroidism Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Secondary Hyperparathyroidism Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Amgen Company Details
Table 65. Amgen Business Overview
Table 66. Amgen Secondary Hyperparathyroidism Treatment Product
Table 67. Amgen Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021) & (US$ Million)
Table 68. Amgen Recent Development
Table 69. OPKO Health Company Details
Table 70. OPKO Health Business Overview
Table 71. OPKO Health Secondary Hyperparathyroidism Treatment Product
Table 72. OPKO Health Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021) & (US$ Million)
Table 73. OPKO Health Recent Development
Table 74. AbbVie Company Details
Table 75. AbbVie Business Overview
Table 76. AbbVie Secondary Hyperparathyroidism Treatment Product
Table 77. AbbVie Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021) & (US$ Million)
Table 78. AbbVie Recent Development
Table 79. Astellas Pharma Company Details
Table 80. Astellas Pharma Business Overview
Table 81. Astellas Pharma Secondary Hyperparathyroidism Treatment Product
Table 82. Astellas Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021) & (US$ Million)
Table 83. Astellas Pharma Recent Development
Table 84. Roche Company Details
Table 85. Roche Business Overview
Table 86. Roche Secondary Hyperparathyroidism Treatment Product
Table 87. Roche Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021) & (US$ Million)
Table 88. Roche Recent Development
Table 89. KAI Pharmaceuticals Company Details
Table 90. KAI Pharmaceuticals Business Overview
Table 91. KAI Pharmaceuticals Secondary Hyperparathyroidism Treatment Product
Table 92. KAI Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021) & (US$ Million)
Table 93. KAI Pharmaceuticals Recent Development
Table 94. Kyowa Hakko Kirin Company Details
Table 95. Kyowa Hakko Kirin Business Overview
Table 96. Kyowa Hakko Kirin Secondary Hyperparathyroidism Treatment Product
Table 97. Kyowa Hakko Kirin Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021) & (US$ Million)
Table 98. Kyowa Hakko Kirin Recent Development
Table 99. Leo Pharma Company Details
Table 100. Leo Pharma Business Overview
Table 101. Leo Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021) & (US$ Million)
Table 102. Leo Pharma Recent Development
Table 103. Takeda Company Details
Table 104. Takeda Business Overview
Table 105. Takeda Secondary Hyperparathyroidism Treatment Product
Table 106. Takeda Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021) & (US$ Million)
Table 107. Takeda Recent Development
Table 108. Sanofi Company Details
Table 109. Sanofi Business Overview
Table 110. Sanofi Secondary Hyperparathyroidism Treatment Product
Table 111. Sanofi Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021) & (US$ Million)
Table 112. Sanofi Recent Development
Table 113. Deltanoid Pharmaceuticals Company Details
Table 114. Deltanoid Pharmaceuticals Business Overview
Table 115. Deltanoid Pharmaceuticals Secondary Hyperparathyroidism Treatment Product
Table 116. Deltanoid Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2016-2021) & (US$ Million)
Table 117. Deltanoid Pharmaceuticals Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Secondary Hyperparathyroidism Treatment Market Share by Type: 2020 VS 2027
Figure 2. Surgery Features
Figure 3. Drugs Features
Figure 4. Vitamin D Features
Figure 5. Calcimimetics Features
Figure 6. Phosphate Binders Features
Figure 7. Global Secondary Hyperparathyroidism Treatment Market Share by Application: 2020 VS 2027
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Secondary Hyperparathyroidism Treatment Report Years Considered
Figure 11. Global Secondary Hyperparathyroidism Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Secondary Hyperparathyroidism Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Secondary Hyperparathyroidism Treatment Market Share by Regions: 2020 VS 2027
Figure 14. Global Secondary Hyperparathyroidism Treatment Market Share by Regions (2022-2027)
Figure 15. Global Secondary Hyperparathyroidism Treatment Market Share by Players in 2020
Figure 16. Global Top Secondary Hyperparathyroidism Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Secondary Hyperparathyroidism Treatment as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Secondary Hyperparathyroidism Treatment Revenue in 2020
Figure 18. Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Type (2016-2021)
Figure 19. Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Type (2022-2027)
Figure 20. North America Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Secondary Hyperparathyroidism Treatment Market Share by Type (2016-2027)
Figure 22. North America Secondary Hyperparathyroidism Treatment Market Share by Application (2016-2027)
Figure 23. North America Secondary Hyperparathyroidism Treatment Market Share by Country (2016-2027)
Figure 24. United States Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Secondary Hyperparathyroidism Treatment Market Share by Type (2016-2027)
Figure 28. Europe Secondary Hyperparathyroidism Treatment Market Share by Application (2016-2027)
Figure 29. Europe Secondary Hyperparathyroidism Treatment Market Share by Country (2016-2027)
Figure 30. Germany Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Share by Region (2016-2027)
Figure 40. China Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Secondary Hyperparathyroidism Treatment Market Share by Type (2016-2027)
Figure 48. Latin America Secondary Hyperparathyroidism Treatment Market Share by Application (2016-2027)
Figure 49. Latin America Secondary Hyperparathyroidism Treatment Market Share by Country (2016-2027)
Figure 50. Mexico Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Share by Country (2016-2027)
Figure 56. Turkey Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Amgen Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2016-2021)
Figure 60. OPKO Health Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2016-2021)
Figure 61. AbbVie Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2016-2021)
Figure 62. Astellas Pharma Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2016-2021)
Figure 63. Roche Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2016-2021)
Figure 64. KAI Pharmaceuticals Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2016-2021)
Figure 65. Kyowa Hakko Kirin Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2016-2021)
Figure 66. Leo Pharma Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2016-2021)
Figure 67. Takeda Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2016-2021)
Figure 68. Sanofi Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2016-2021)
Figure 69. Deltanoid Pharmaceuticals Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

以下、関連資料のご紹介

世界の多毛症治療市場規模・現状・予測（2021年-2027年）

Global Hirsutism Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z2853 2021年4月 96Pages
QYResearch社発行の本調査資料では、多毛症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（特発性多毛症、二次多毛症、その他）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓...

世界の排水処理プラント市場規模・現状・予測（2021年-2027年）

Global Effluent Treatment Plant Market Size, Status and Forecast 2021-2027
QYR2104Z2049 2021年4月 97Pages
QYResearch社発行の本調査資料では、排水処理プラントのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（予備処理、二次・生物学的処理、三次・高度・消毒処理）、用途別市場規模（食品産業、石油・ガス、電力産業、化学産業、製紙工場、その他）、主要...

世界の体位性頻脈症候群（POTS）治療市場規模・現状・予測（2021年-2027年）

Global Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4716 2021年4月 98Pages
QYResearch社発行の本調査資料では、体位性頻脈症候群（POTS）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（一次フォーム、二次フォーム）、用途別市場規模（病院、診療所、外来手術センター、研究所）、主要地域別市場規模（北米、アメリ...

世界の肢端紅痛症治療市場規模・現状・予測（2021年-2027年）

Global Erythromelalgia Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z2244 2021年4月 116Pages
QYResearch社発行の本調査資料では、肢端紅痛症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（治療薬、治療）、用途別市場規模（原発性肢端紅痛症、続発性肢端紅痛症）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、...

世界のスウェーデンポルフィリン症治療市場規模・現状・予測（2021年-2027年）

Global Swedish Porphyria Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z5520 2021年4月 99Pages
QYResearch社発行の本調査資料では、スウェーデンポルフィリン症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（350mg、313mg）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国...

世界の後天性血友病A治療市場規模・現状・予測（2021年-2027年）

Global Acquired hemophilia A Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0029 2021年4月 97Pages
QYResearch社発行の本調査資料では、後天性血友病A治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（200IU、250IU）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、イン...

世界の生産水処理システム市場規模・現状・予測（2021年-2027年）

Global Produced Water Treatment Systems Market Size, Status and Forecast 2021-2027
QYR2104Z4805 2021年4月 125Pages
QYResearch社発行の本調査資料では、生産水処理システムのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（一次処理、二次処理、複数処理）、用途別市場規模（オンショア、オフショア）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本...

世界の急性間欠性ポルフィリン症（AIP）治療市場規模・現状・予測（2021年-2027年）

Global Acute Intermittent Porphyria Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0060 2021年4月 92Pages
QYResearch社発行の本調査資料では、急性間欠性ポルフィリン症（AIP）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（350mg、313mg）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日...

世界のアデノシンデアミナーゼ欠損症（ADA）治療市場規模・現状・予測（2021年-2027年）

Global Adenosine Deaminase Deficiency Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0096 2021年4月 96Pages
QYResearch社発行の本調査資料では、アデノシンデアミナーゼ欠損症（ADA）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アダーゲン、レブコビ）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、...

世界の軟骨無形成症治療市場規模・現状・予測（2021年-2027年）

Global Achondroplasia Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0013 2021年4月 92Pages
QYResearch社発行の本調査資料では、軟骨無形成症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（RBM-007、TA-46、B-701、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロ...

世界の骨・ミネラル代謝異常治療市場規模・現状・予測（2021年-2027年） Bone minerals are the inorganic compounds of the bone tissue that helps in strengthening the bones with its plate and globular structures. These minerals are formed from carbonated hydroxyapatite. Bone minerals are dynamic in living beings, it is continuously reabsorbed and build anew in the bone re…
世界のドライアイ治療薬・治療用装置市場規模・現状・予測（2021年-2027年） Dry eye disease is a condition that affects the tear film and ocular surface. It is medically known as keratoconjunctivitis sicca. It is an ocular disorder caused by the lack of tear fluid to lubricate the eyes. There are primarily two types of dry eye conditions. One is aqueous tear-deficient dry e…
世界の萎縮性胃炎治療市場規模・現状・予測（2021年-2027年） Atopic gastritis is chronic inflammation of gastric mucosa, and it is a histopathological condition associated with gastric glandular cell and replacement by fibrous tissue, intestinal type epithelium, and pyloric type glands. It mainly associated H. Pylori bacterial infection, and autoimmunity dire…
世界のビタミンD欠乏症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Vitamin D Deficiency Treatment Market The global Vitamin D Deficiency Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data int…
世界の変形性関節症治療市場規模・現状・予測（2021年-2027年） Osteoarthritis (OA) is a type of joint disease that results from breakdown of joint cartilage and underlying bone. The most common symptoms are joint pain and stiffness. Initially, symptoms may occur only following exercise, but over time may become constant. Other symptoms may include joint swellin…